CompletedPhase 3NCT00492258
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
Studying Clear cell papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medical Research Council
- Principal Investigator
- Timothy EisenCancer Research UK
- Intervention
- sorafenib tosylate(drug)
- Enrollment
- 1656 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2012
Study locations (30)
- Royal Bournemouth Hospital, Bournemouth, England, United Kingdom
- Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
- Queen's Hospital, Burton-on-Trent, England, United Kingdom
- Addenbrooke's Hospital, Cambridge, England, United Kingdom
- Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England, United Kingdom
- Derbyshire Royal Infirmary, Derby, England, United Kingdom
- Dorset County Hospital, Dorchester, England, United Kingdom
- Gloucestershire Royal Hospital, Gloucester, England, United Kingdom
- Diana Princess of Wales Hospital, Grimsby, England, United Kingdom
- Princess Royal Hospital at Hull and East Yorkshire NHS Trust, Hull, England, United Kingdom
- Ipswich Hospital, Ipswich, England, United Kingdom
- Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
- Leicester Royal Infirmary, Leicester, England, United Kingdom
- Lincoln County Hospital, Lincoln, England, United Kingdom
- Saint Bartholomew's Hospital, London, England, United Kingdom
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00492258 on ClinicalTrials.govOther trials for Clear cell papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05665361Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)National Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05287945Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell CarcinomaOncorena AB
- RECRUITINGPHASE1NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05122546CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerCity of Hope Medical Center
See all trials for Clear cell papillary renal cell carcinoma →